New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 23, 2014
04:55 EDTACRX, ACRX, BLRX, BLRX, CRIS, CRIS, NEO, NEO, PRTA, PRTA, PTCT, PTCT, LGND, LGND, GALE, GALE, IPCI, IPCIRoth Capital to hold a conference
ROTH Healthcare Corporate Access Day to be held in London, England on June 23-24.
News For ACRX;BLRX;CRIS;NEO;PRTA;PTCT;LGND;GALE;IPCI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 31, 2014
07:06 EDTBLRXBioLineRx announces publication of IK-5001 Phase 1,2 study
BioLineRx announced publication of the results of a previous Phase 1,2 study for IK-5001, currently named Bioabsorbable Cardiac Matrix. This first-in-man pilot study, which was completed in 2010, demonstrates that intracoronary deployment of BCM is feasible and well tolerated. BCM, which was out-licensed to Bellerophon in 2009 for further development and commercialization, is in the midst of the PRESERVATION I study, a CE Mark registration trial at over 80 sites worldwide, 16 of which are in the U.S. To date, over 280 patients have been enrolled in the study, which is designed to enroll a total of approximately 300 patients. Enrollment is expected to be completed by the end of this year, with study completion anticipated in mid-2015.
October 30, 2014
07:13 EDTNEONeoGenomics raises FY14 EPS to 1c-3c from 0c-3c, consensus 1c
Subscribe for More Information
07:13 EDTNEONeoGenomics sees Q4 EPS 0c-1c, consensus 0c
Sees Q4 revenue $23M-$24.5M, consensus $22.91M
07:12 EDTNEONeoGenomics reports Q3 EPS excl. items 1c, consensus (1c)
Subscribe for More Information
October 28, 2014
07:21 EDTCRISCuris announces allowance of U.S. patent
Curis announced the receipt of a Notice of Allowance of a U.S. patent that covers a broad genus of compounds that target histone deacetylase, or HDAC, and phosphoinositide 3-kinase, or PI3K, activities in a single chemical structure including CUDC-907, Curis' oral, dual HDAC and PI3K small molecule inhibitor that is currently being studied in Phase 1 clinical trials. This patent, along with prior patents issued to Curis, further strengthens the Company's intellectual property portfolio of compounds including CUDC-907 that inhibit HDAC and PI3K enzymes in a single small molecule for the treatment of certain human diseases. Collectively, these patents generically cover composition-of-matter and methods of use of CUDC-907 as well as a broad range of proprietary chemical entities that target HDAC and PI3K enzymes, and in some instances mammalian target of rapamycin, within a single molecule for the treatment of certain human diseases.
October 27, 2014
08:05 EDTPTCTPTC Therapeutics announces positive data from Translarna study
Subscribe for More Information
08:03 EDTLGNDLigand sees Q4 EPS 57c-62c, consensus $67c
Subscribe for More Information
08:02 EDTLGNDLigand still sees FY14 EPS $1.50-$1.55, consensus $1.54
Subscribe for More Information
08:01 EDTLGNDLigand reports Q3 EPS 36c, consensus 31c
Subscribe for More Information
07:23 EDTACRXAmerican College of Surgeons holds a conference
Subscribe for More Information
07:18 EDTIPCIIntellipharmaceutics says FDA gives Toronto facility 'Acceptable' classification
Subscribe for More Information
October 24, 2014
07:56 EDTACRXAcelRx management to meet with BofA/Merrill
Meeting to be held in New York on October 29 hosted by BofA/Merrill.
October 23, 2014
09:23 EDTLGNDLigand price target raised to $121.50 from $92 at Roth Capital
Subscribe for More Information
October 22, 2014
17:19 EDTIPCIIntellipharmaceutics reports positive results from Regabatin phase 1 trials
Intellipharmaceutics provided an update on the progress of its Regabatin XR product development. Regabatin XR pregabalin extended release capsules are the company's non-generic pregabalin formulations. The company has recently conducted and analyzed the results of six phase I clinical trials involving a twice-a-day formulation and a once-a-day formulation. For formulations directed to certain indications which include fibromyalgia, the results suggested that Regabatin XR 82.5 mg twice-a-day, or BID, dosage was comparable in bioavailability to Lyrica 50 mg three-times-a-day, or TID, dosage. For formulations directed to certain other indications which include neuropathic pain associated with diabetic peripheral neuropathy, the results suggested that Regabatin XR 165 mg once-a-day dosage was comparable in bioavailability to Lyrica 75 mg BID dosage. Pregabalin is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, spinal cord injury and fibromyalgia. A controlled-release version of pregabalin should reduce the number of doses patients take, which could improve patient compliance, and therefore possibly enhance clinical outcomes. Plans are underway to initiate an investigational new drug application under the new drug application 505b2 regulatory pathway with the FDA, with a view to possible commercialization in the U.S. following the Dec. 30, 2018 expiry of the patent covering the pregabalin molecule.
14:08 EDTGALEGalena files to sell 2M shares of common stock for holders
Subscribe for More Information
07:19 EDTACRXAcelRx's Zalviso for abdominal pain shows positive Phase 3 results
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use